And if we look at the share price and the total shareholder return then over the recent years we did outperform our peers in the world market but also if ...
The independent Alcon directors had been widely expected to say the Novartis price was too low but, if necessary, the Swiss group could simply replace the ...
The maker of blood pressure drug Diovan and anticancer drug Gleevec offered a positive outlook for 2010, predicting mid-to-high single digit growth in its ...
Email this story